MA
Manju Ashish Kesharwani
About Manju Ashish Kesharwani
Data last updated:
Manju Ashish Kesharwani has 7 years in corporate governance. Holds Director role. Currently with 1 company, including Brionova Pharmaceutical Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Brionova Pharmaceutical Private Limited at ₹1.19 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Brionova Pharmaceutical Private Limited U51909PN2019PTC184863 | Director | 17 Jun 2019 | 2019 | ₹1.19 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Manju Ashish Kesharwani
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Manju Ashish Kesharwani
Manju Ashish Kesharwani has 7 years in corporate governance. Holds Director role. Currently with 1 company, including Brionova Pharmaceutical Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Brionova Pharmaceutical Private Limited at ₹1.19 Cr (FY 2025).
Manju Ashish Kesharwani is associated with 1 company as Director, including Brionova Pharmaceutical Private Limited (₹1.19 Cr).
Manju Ashish Kesharwani has expertise in General Business.
Manju Ashish Kesharwani has 7 years in corporate governance.
By reported revenue, the largest current company of Manju Ashish Kesharwani is Brionova Pharmaceutical Private Limited, with revenue of ₹1.19 Cr (FY 2025).
Manju Ashish Kesharwani currently holds positions at 1 company: Brionova Pharmaceutical Private Limited (₹1.19 Cr).